Lenalidomida Zentiva

Lenalidomide, the active ingredient in Lenalidomida Zentiva, is an immunomodulatory imide drug presented as an oral tablet for oral use in adult patients. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with del(5q) chromosome abnormality under specialist supervision.

GNH USA supplies Lenalidomida Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company follows established quality assurance processes and holds regulatory approvals across the European Union, ensuring reliable supply chains for critical oncology therapies.

Lenalidomide is employed in the management of specific hematologic cancers and bone‑marrow failure syndromes, where it modulates the immune environment and inhibits angiogenesis.

- Multiple myeloma: improves progression‑free and overall survival in patients with relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can lead to cytogenetic remission.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: decreased white blood cell count, increasing infection risk. - Thrombocytopenia: reduced platelet count, may cause bruising or bleeding. - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs, requiring immediate medical attention. - Severe infections: opportunistic infections such as pneumonia or sepsis. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Before initiating Lenalidomide therapy, clinicians should observe several safety precautions to minimize risks. - Blood count monitoring: perform complete blood count regularly to detect neutropenia or thrombocytopenia. - Thromboembolic risk assessment: evaluate patient history and consider prophylactic anticoagulation when indicated. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception for both male and female patients. - Renal function adjustment: assess kidney function and adjust dose in moderate to severe impairment. - Store at below 25°C: keep tablets in the original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (ketoconazole, itraconazole): may raise lenalidomide levels. - Thalidomide or pomalidomide: combined teratogenic and hematologic toxicity. - Anticoagulants (warfarin, DOACs): increased bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may reduce drug exposure. - NSAIDs: may exacerbate neutropenia or gastrointestinal side effects.